161 related articles for article (PubMed ID: 37997010)
21. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
22. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
23. Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Zhang Y; Li Y; Li C; Zhao Y; Xu L; Ma S; Lin F; Xie Y; An J; Wang S
Phytomedicine; 2023 Sep; 118():154957. PubMed ID: 37478683
[TBL] [Abstract][Full Text] [Related]
24. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
25. Renal handling of uric acid in gout: impaired tubular transport of urate not dependent on serum urate levels.
García Puig J; Mateos Antón F; López Jiménez M; Conthe Gutiérrez P
Metabolism; 1986 Dec; 35(12):1147-53. PubMed ID: 3784914
[TBL] [Abstract][Full Text] [Related]
26. Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.
Yano H; Tamura Y; Kobayashi K; Tanemoto M; Uchida S
Clin Exp Nephrol; 2014 Feb; 18(1):50-5. PubMed ID: 23584883
[TBL] [Abstract][Full Text] [Related]
27. Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Zhang Y; Jin L; Liu J; Wang W; Yu H; Li J; Chen Q; Wang T
J Ethnopharmacol; 2018 Mar; 214():29-36. PubMed ID: 29233733
[TBL] [Abstract][Full Text] [Related]
28. Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion.
Torres RJ; de Miguel E; Bailén R; Banegas JR; Puig JG
J Rheumatol; 2014 Sep; 41(9):1863-70. PubMed ID: 25128519
[TBL] [Abstract][Full Text] [Related]
29. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
Vitart V; Rudan I; Hayward C; Gray NK; Floyd J; Palmer CN; Knott SA; Kolcic I; Polasek O; Graessler J; Wilson JF; Marinaki A; Riches PL; Shu X; Janicijevic B; Smolej-Narancic N; Gorgoni B; Morgan J; Campbell S; Biloglav Z; Barac-Lauc L; Pericic M; Klaric IM; Zgaga L; Skaric-Juric T; Wild SH; Richardson WA; Hohenstein P; Kimber CH; Tenesa A; Donnelly LA; Fairbanks LD; Aringer M; McKeigue PM; Ralston SH; Morris AD; Rudan P; Hastie ND; Campbell H; Wright AF
Nat Genet; 2008 Apr; 40(4):437-42. PubMed ID: 18327257
[TBL] [Abstract][Full Text] [Related]
30. Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail.
Wu H; Wang Y; Ren Z; Li Y; Huang J; Lin Z; Zhang B
Front Immunol; 2022; 13():1074867. PubMed ID: 36569836
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapies in the long-term management of hyperuricaemia and gout.
Stamp LK; O'Donnell JL; Chapman PT
Intern Med J; 2007 Apr; 37(4):258-66. PubMed ID: 17388867
[TBL] [Abstract][Full Text] [Related]
32. DKB114, A Mixture of
Lee YS; Kim SH; Yuk HJ; Kim DS
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30274153
[No Abstract] [Full Text] [Related]
33. Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.
Méndez-Salazar EO; Martínez-Nava GA
Rheumatol Int; 2022 Mar; 42(3):403-412. PubMed ID: 34586473
[TBL] [Abstract][Full Text] [Related]
34. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
[TBL] [Abstract][Full Text] [Related]
35. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease?
Orhan IE; Deniz FSS
Curr Pharm Des; 2021; 27(2):143-158. PubMed ID: 32723252
[TBL] [Abstract][Full Text] [Related]
36. Purine metabolism in women with primary gout.
Puig JG; Mateos FA; Miranda ME; Torres RJ; de Miguel E; Pérez de Ayala C; Gil AA
Am J Med; 1994 Oct; 97(4):332-8. PubMed ID: 7942934
[TBL] [Abstract][Full Text] [Related]
37. Uricase-deficient rats with similarly stable serum uric acid to human's are sensitive model animals for studying hyperuricemia.
Gao Y; Yu Y; Qin W; Fan N; Qi Y; Chen H; Duan W
PLoS One; 2022; 17(3):e0264696. PubMed ID: 35239728
[TBL] [Abstract][Full Text] [Related]
38. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms and rationale for uricase use in patients with gout.
Schlesinger N; Pérez-Ruiz F; Lioté F
Nat Rev Rheumatol; 2023 Oct; 19(10):640-649. PubMed ID: 37684360
[TBL] [Abstract][Full Text] [Related]
40. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
